title: [Intrathecal injection of muscarinic receptors or GDNF antisense oligonucleotides inhibits the increase of c-Fos expression in locus coeruleus of morphine-withdrawal rats].
abstract: The antisense approach and immunohistochemistry were used to study the effects of different muscarinic receptor (M) subtypes and glial cell derived neurotrophic factor (GDNF) on the scores of morphine-withdrawal syndrome and the expression of c-Fos in locus coeruleus (LC). Intrathecal injection of M2 receptor antisense oligonucleotides (M2AS-oligo) or GDNF antisense oligonucleotides (GDNFAS-oligo) decreased the scores of morphine withdrawal syndrome. The expression of c-Fos positive neurons in the LC increased in morphine-dependent rats and increased to a greater extent after the injection of naloxone (4mg/kg, ip) in morphine dependent rats. Intrathecal injection of M2AS-oligo or GDNFAS-oligo inhibited the increase of c-Fos expression in LC during morphine withdrawal, but there was no effect in case of M1AS-oligo. The results suggest that M2 receptor of spinal cord mediates the neural activation of LC during morphine withdrawal. And the interaction between neurons and glial cells may be involved in the ascending activation process.
authors.affiliation: Ningbo Institute of Microcirculation & Henbane, Ningbo Aaddiction Research and Treatment Center, Ningbo 315010. lihufen@163.com
authors.forename: Hui Fen
authors.initials: HF
authors.lastname: Liu
authors.forename: Wen Hua
authors.initials: WH
authors.lastname: Zhou
authors.forename: Shuai En
authors.initials: SE
authors.lastname: Tang
authors.forename: Miao Jun
authors.initials: MJ
authors.lastname: Lai
authors.forename: Sheng
authors.initials: S
authors.lastname: Liu
authors.forename: Wei Sheng
authors.initials: WS
authors.lastname: Chen
authors.forename: Guo Dong
authors.initials: GD
authors.lastname: Yang
mesh_terms: D000818:Animals; D015870:Gene Expression / Q000187:drug effects; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D007150:Immunohistochemistry; D007278:Injections, Spinal; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000502:physiology*; D013375:Substance Withdrawal Syndrome / Q000378:metabolism*
chemical_list: D051100:Glial Cell Line-Derived Neurotrophic Factor; D018727:Muscarinic Antagonists; D016376:Oligonucleotides, Antisense; D016760:Proto-Oncogene Proteins c-fos; D011976:Receptors, Muscarinic; D009020:Morphine